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JoObjective: Mitochondria-derived reactive oxygen species
(ROS) play important roles in the development of
cardiovascular disease highlighting the need for novel
targeted therapies. This study assessed the potential
therapeutic benefit of combining the mitochondria-specific
antioxidant, MitoQ10, with the low-dose angiotensin
receptor blocker (ARB), losartan, on attenuation of
hypertension and left ventricular hypertrophy. In parallel,
we investigated the impact of MitoQ10 on cardiac
hypertrophy in a neonatal cardiomyocyte cell line.
Methods and results: Eight-week-old male stroke-prone
spontaneously hypertensive rats (SHRSPs, n¼8–11) were
treated with low-dose losartan (2.5mg/kg per day);
MitoQ10 (500mmol/l); a combination of MitoQ10 and
losartan (MR L); or vehicle for 8 weeks. Systolic pressure
and pulse pressure were significantly lower in MR L rats
(167.12.9mmHg; 50.2 2.05mmHg) than in untreated
SHRSP (206.6 9mmHg, P<0.001; 63.72.7mmHg,
P¼0.001) and demonstrated greater improvement than
MitoQ10 or low-dose losartan alone, as measured by
radiotelemetry. Left ventricular mass index was significantly
reduced from 22.80.74 to 20.10.61mg/mm in the
combination group (P<0.05). Picrosirius red staining
showed significantly reduced cardiac fibrosis in MR L rats
(0.820.22A.U.) compared with control
(5.941.35A.U., P<0.01). In H9c2 neonatal rat
cardiomyocytes, MitoQ10 significantly inhibited angiotensin
II mediated hypertrophy in a dose-dependent manner
(500 nmol/l MitoQ10 153.73.1microns vs. angiotensin II
200.1 3.6microns, P<0.001).
Conclusion: Combining MitoQ10 and low-dose losartan
provides additive therapeutic benefit, significantly
attenuating development of hypertension and reducing left
ventricular hypertrophy. In addition, MitoQ10 mediates a
direct antihypertrophic effect on rat cardiomyocytes
in vitro. MitoQ10 has potential as a novel therapeutic
intervention in conjunction with current antihypertensive
drugs.
Keywords: cardiac fibrosis, cardiac hypertrophy,
hypertension, mitochondria, reactive oxygen species
Abbreviations: A.U., arbitrary units; ACE, angiotensin-
converting enzyme; AngII, angiotensin II; ARB, angiotensinopyright © Lippincott Williams & Wilkins. Unauth
urnal of Hypertensionreceptor blocker; AUC, area under curve; CMI, cardiac
mass index; De, external diameter; Di, internal diameter;
dTPP, decyl triphenylphosphonium; eGFR, estimated
glomerular filtration rate; KCl, potassium chloride;
L-NAME, NG-nitro-L-arginine methyl ester; LVMI, left
ventricular mass index; MþL, MitoQ10 and losartan; MRA,
mesenteric resistance artery; NOS, nitric oxide synthase;
ROS, reactive oxygen species; SHRSP, stroke prone
spontaneously hypertensive ratINTRODUCTIONA
ccumulating evidence demonstrates that mito-
chondria-derived reactive oxygen species (ROS)
play an important role in the development of
cardiovascular disease [1,2]. Conventional antioxidants
cannot impact on mitochondria-derived ROS owing to their
limited accumulation within mitochondria, highlighting the
need for targeted therapies. Previously, we demonstrated
that oral administration of the mitochondria-targeted anti-
oxidant MitoQ10 attenuates the development of hyperten-
sion, improves endothelial nitric oxide bioavailability and
reduces cardiac hypertrophy in the stroke-prone spon-
taneously hypertensive rat (SHRSP) [3]. Although the
MitoQ10-mediated reduction in blood pressure was modest,
it may represent an important novel therapeutic agent for
resistant hypertension and end-organ damage if combined
with established antihypertensive drugs. Resistant hyper-
tension remains a common problem with an estimated
prevalence of 20–30%, despite a three-drug regimen [4].orized reproduction of this article is prohibited.
DOI:10.1097/HJH.0000000000000054
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mechanisms, which are not fully addressed by current
antihypertensive therapies. Combining a mitochondria-
targeted antioxidant such as MitoQ10 with commonly used
antihypertensive agents may provide additive effects
against the morbidity and mortality associated with
resistant hypertension.
Studies by Dai et al. [5,6] indicate a critical role of
mitochondrial ROS in cardiac hypertrophy, fibrosis and
failure strengthening the rationale for mitochondria-tar-
geted drugs. Our previous studies suggest a direct effect
of MitoQ10 on cardiac hypertrophy, demonstrated by a
significant reduction in cardiac mass index (CMI) despite
relatively small blood pressure attenuation [3]. Similarly,
direct blood pressure independent effects on cardiac hyper-
trophy have been demonstrated with low-dose angioten-
sin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) [7–9]. Combining MitoQ10 with a
low-dose commonly used antihypertensive agent may
achieve additional risk reduction beyond blood pressure
lowering by addressing both cytosolic and mitochondrial
mechanisms of ROS generation. The aims of this study were
to investigate the potential complementary effects of a
combined therapeutic strategy on the development of
hypertension and cardiac hypertrophy using the mitochon-
dria-targeted antioxidant MitoQ10 and a low-dose ARB,
losartan. In parallel, we investigated the contribution of
mitochondrial oxidative damage to cardiomyocyte hyper-
trophy in vitro using H9c2 neonatal cardiomyocytes. These
studies suggest new therapeutic interventions for resistant
hypertension and related organ damage in humans.
MATERIALS ANDMETHODS
An expanded Methods section is available in the Online
Data Supplement, http://links.lww.com/HJH/A299.
In-vivo experimental procedures
An inbred colony of SHRSP has been maintained at the
University of Glasgow since 1991. Animals were housed
under 12 h light/dark cycles at ambient temperature and
were maintained on normal rat chow (Rat and Mouse No. 1
maintenance diet, Special Diet Services). All studies were
conducted in accordance with the Animals Scientific Pro-
cedures Act 1986. Eight-week-old male SHRSP (8–11 rats
per group) were treated with low-dose losartan (2.5mg/kg
per day); MitoQ10 (500mmol/l); a combination of MitoQ10
and losartan (Mþ L); or vehicle for 8 weeks. MitoQ10 was
administered in drinking water, and losartan potassium
(Sigma-Aldrich, Gillingham, Dorset, UK) administered daily
and mixed with highly palatable baby food. SBP was
measured by tail-cuff plethysmography [10,11] for the first
4 weeks of study. At 12 weeks of age, rats were implanted
with radiotelemetry probes (Dataquest IV telemetry system;
Data Sciences International, St Paul, Minnesota, USA) for
haemodynamic measurement over the final 4 weeks of
treatment [3,12]. Metabolic cages were used for the
measurement of volume intake, urine output and collection
of 24-h urine samples from control and treated rats at
16 weeks of age. At sacrifice, blood samples were taken
by cardiac puncture, followed by measurement of heartCopyright © Lippincott Williams & Wilkins. Unaut
556 www.jhypertension.comweight, left ventricle as well as septum weight and kidney
weight for the calculation of CMI, left ventricular mass index
and renal mass index, respectively (CMI, LVMI, RMI cor-
rected for tibia length). Heart apexes were fixed in 10%
formalin for histological fibrosis assessment by picrosirius
red staining. Aortae were taken for organ bath pharma-
cology and liver samples snap-frozen in liquid nitrogen.Ex-vivo experimental procedures
Organ bath pharmacology
Organ bath pharmacology was used as described pre-
viously [3,11] to test contractile responses in aorta from
control and drug-treated SHRSP. Vessels (approximately
4mm in length) were pretreated with potassium chloride
(KCl, 100mmol/l), followed by construction of cumula-
tive concentration–response curves to phenylephrine
(10 nmol/l to 10mmol/l in the absence and presence of
NG-nitro-L-arginine methyl ester (L-NAME, 100mmol/l) to
inhibit nitric oxide species (NOS). Consecutive dose–
response curves were carried out in the same vessel,
measured first in the absence of L-NAME, followed by
two washes with Krebs’ buffer and then in the presence
of L-NAME. The difference in tension in the absence and
presence of L-NAME provides a measure of basal NO
bioavailability and was calculated over the full dose–
response curve and expressed as area under the curve
(AUC). In addition, the rings were preconstricted to the
EC50 of phenylephrine and a concentration–response
curve for relaxation to carbachol (10 nmol/l to 10mmol/l)
was obtained to measure stimulated NO release for which
AUC was calculated. Responses to phenylephrine were
standardized against the initial contractile response to KCl.
Histology
Five-micrometre paraffin-embedded sections of heart apex
were cut and deparaffinized with two washes in Histoclear
(Fisher Scientific, Loughborough, UK) followed by rehy-
dration through an ethanol concentration gradient. Fibrosis
was assessed using picrosirius red staining (Sigma-Aldrich)
specific for collagen type I and III. Sections were incubated
under dark conditions in 0.1% picrosirius red solution,
washed, rehydrated and cover-slip mounted. A colour
threshold application was used to measure the average
intensity of picrosirius red stain in five sections per heart
apex from 3–8 rats per treatment group (ImageProPlus 4.1;
Media Cybernetics, Marlow, UK). This involved transform-
ation of pixel values to optical density units using the Area
of Interest selection tool and Macro from the ImageProPlus
software [13].
Biochemical analysis
Urine sodium, potassium, urea and total protein levels were
measured by routine biochemical analysis (Biochemistry
Department, Gartnavel General Hospital, Glasgow, UK).
Urinary and plasma creatinine were assessed for estimated
glomerular filtration rate (eGFR) by the QuantiChrom
Creatinine Assay Kit [Universal Biologicals (Cambridge)
Ltd, Cambridge, UK] and urinary protein concentrations
assessed by bicinchoninic acid (BCA) Protein Assay (Pierce,horized reproduction of this article is prohibited.
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Combined benefit of MitoQ10 and losartan on cardiovascular functionRockford, Illinois, USA). Lipid peroxidation in liver samples
was determined by malondialdehyde (MDA) assay kit
(Bioxytech LPO-586 Assay Kit; OxisResearch, Portland,
Oregon, USA) according to manufacturer’s instructions
and normalized to protein concentration.Copyright © Lippincott Williams & Wilkins. Unauth
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FIGURE 1 Effect of MitoQ10 treatment alone and in combination with low-dose losartan
raphy and radiotelemetry was reduced by MitoQ10 and losartan alone, and demonstrate
#P¼0.006 vs. MitoQ10 and $P¼0.05 vs. losartan). (b) DBP was significantly reduced by
control). (c) Pulse pressure shows small but significant reduction in losartan-only treated
P¼0.001 vs. control; #P¼0.01 vs. MitoQ10, zP¼0.057 vs. losartan only). (d) Heart rat
control, $P¼0.001 vs. losartan). (e) Night-time heart rate was significantly lowered by M
only (P¼0.02 P¼0.001 vs. control, $P¼0.006 $$P<0.001 vs. losartan only; n¼8–1
Journal of HypertensionIn-vitro treatment of cardiomyocytes with
MitoQ10
In-vitro assays were conducted in the H9c2 immortalized
cardiomyocyte cell line derived from rat neonatal cardio-
myocytes [14,15]. Cells were pretreated with MitoQ10 or theorized reproduction of this article is prohibited.
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on the haemodynamic profile of SHRSP. (a) SBP measured by tail-cuff plethysmog-
d greatest reduction with combined therapy (P¼0.004, P<0.001 vs. control;
individual and combination treatment (P¼0.032, P¼0.005, P¼0.003 vs.
rats, and more pronounced reduction with combination therapy (P¼0.025,
e measured by radiotelemetry was significantly reduced by MitoQ10 (
P¼0.012 vs.
itoQ10 alone and by combination treatment compared with control and losartan
1).
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McLachlan et al.control compound decyl triphenylphosphonium (dTPP)
(10–500 nmol/l) for 18 h prior to angiotensin II (AngII)
stimulation (100 nmol/l). After 96 h, cells were fixed with
2% paraformaldehyde, stained overnight with 2% crystal
violet and cell size measured using ImageProPlus 4.1 soft-
ware (Media Cybernetics). For each condition, 180 random
cells were measured from 18 fields of view; experiments
were repeated in triplicate on three independent occasions.Copyright © Lippincott Williams & Wilkins. Unaut
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FIGURE 2 Effect of MitoQ10 alone and in combination with low-dose losartan on
stimulation. (b) Nitric oxide bioavailability measured as the difference in contraction to PE
calculated for basal NO bioavailability curves. Basal NO bioavailability was significantly in
P<0.01 vs. control. #P<0.05 vs. MitoQ10; n¼7–10). (d) Relaxation to carbachol was
was significantly reduced in losartan-treated rats (P<0.05, n¼5) with trends towards r
558 www.jhypertension.comThe MitoQ10 analogue IBTP was colocalized to mitochon-
dria using confocal microscopy as previously demonstrated
(see supplementary methods, http://links.lww.com/HJH/
A299) [16].
Cell Titre 96R Non-Radioactive Cell Proliferation Assay
(Promega, Southampton, UK) was used according to manu-
facturer’s instructions to test the cytotoxicity of MitoQ10 and
dTPP. A spectrometer (Wallac Victor2 plate-reader; Perkinhorized reproduction of this article is prohibited.
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eduction in the MitoQ10 and combination groups.
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Combined benefit of MitoQ10 and losartan on cardiovascular functionElmer,Turku, Finland)measured absorbanceof 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at
570nm. Experiments were repeated in quadruplicate on
three independent occasions.
Statistical analysis
Results are expressed as mean SEM. In-vivo experiments
were performed with 8–11 rats per group. Repeated-
measures analysis of variance (ANOVA) with Tukey pair-
wise comparison was used to compare radiotelemetry
data. Ex-vivo comparisons were performed by one-way
ANOVA with Tukey’s multiple comparison test. In-vitro
comparisons between groupswere performed by one-way
ANOVA with Bonferoni’s multiple comparison test. Stat-
istical significance was considered with P values less
than 0.05.
RESULTS
Average day-time SBP of control SHRSP increased from
129.0 4.9mmHg to a maximum of 206.6 9.0mmHg over
the 8-week study (Fig. 1a). MitoQ10 or low-dose losartan
alone resulted in significant attenuation of SBP (MitoQ10;
185.5 6.0mmHg, P¼ 0.032, Los; 172.9 1.7mmHg,
P¼ 0.004). When both drugs were used in combination,
there was a highly significant reduction in SBP compared
with control (167.1 2.9mmHg, P< 0.001), which was
significantly lower than either treatment alone. DBP was
significantly reduced by either drug alone (MitoQ10;
126.3 3.7mmHg, P¼ 0.032, Los; 118.2 0.77mmHg,
P¼ 0.003) or in combination (116.3 2.1mmHg,
P¼ 0.005) compared with control (142.6 6.5mmHg,
Fig. 1b) but suggest no additive benefit of combined
therapy. Pulse pressure was significantly reduced by com-
bination treatment (50.2 2.1mmHg, P¼ 0.001) compared
with control (63.7 2.7mmHg) and indicates additional
benefit compared with either drug alone (Fig. 1c). Heart
rate was significantly lower in MitoQ10-treated SHRSP
(329.3 3.2 bpm) than in control (351.6 4.3 bpm,
P¼ 0.012, Fig. 1d). Night-time heart rate, when the rats
are most active, was significantly reduced in MitoQ10 alone
and combination treatment groups (Fig. 1e) compared with
control or losartan only. Tibia length, fluid excretion/intake
ratio and motor activity were not significantly different
between groups (Supplementary figure i, http://links.
lww.com/HJH/A299).
Basal nitric oxide bioavailability in aorta from control
and drug-treated SHRSP is illustrated in Fig. 2a andCopyright © Lippincott Williams & Wilkins. Unauth
TABLE 1. Effect of MitoQ10 alone and in combination with low-dose
Control
Kidney:tibia ratio (mg/mm) 27.11.06
eGFR (ml/min per g kidney weight) 0.250.03
Urinary protein (mg/ml per 24 h) 120.715.4
Urinary Naþ (mmol/24h) 0.920.21
Urinary Kþ (mmol/24h) 2.060.28
Urea (mmol/24 h) 6.990.54
Values are means SEM; n¼8–11 rats per group. eGFR, estimated glomerular filtration rate.
P<0.05 compared with untreated control.
Journal of Hypertensionexpressed as AUC in Fig. 2b. Basal nitric oxide bioavail-
ability was significantly improved in losartan-treated
SHRSP compared with control (P< 0.05) and in combi-
nation treatment compared with control (P< 0.05) and
MitoQ10 only (
#P< 0.05). Relaxation to carbachol was not
significantly different in aortic rings from control and drug-
treated SHRSP (Fig. 2c). Lipid peroxidation, measured by
MDA assay, was used to assess oxidative stress in liver
samples from control and drug-treated SHRSP (Fig. 2d).
Treatment with losartan only resulted in a significant
decrease in liver MDA levels (P< 0.05). The other treat-
ment groups demonstrated similar trends but were not
significantly different to untreated controls. No significant
differences were observed for basal superoxide pro-
duction in aortic rings or plasma lipid peroxidation
(Supplementary Figure ii, http://links.lww.com/HJH/
A299).
Kidney and urine characteristics for MitoQ10, losartan
and combination-treated SHRSP were assessed (Table 1).
There were no significant differences in kidney mass index,
eGFR or urinary levels of Naþ, Kþ or urea between control
and treatment groups. However, total urinary protein
excretion was significantly reduced in MitoQ10-treated rats
(P< 0.05) with a similar trend in the combination therapy
group.
Combination treatment significantly reduced cardiac
mass index (CMI) (Mþ L 27.3 0.77mg/mm, control
30.9 0.98mg/mm, P< 0.05) and LVMI (Mþ L
20.1 0.61mg/mm, control 22.8 0.74mg/mm; P< 0.05)
compared with untreated controls (Fig. 3a, b). Cardiac
fibrosis was assessed by picrosirius red staining (Fig. 3c)
and collagen I and III immunohistochemistry (Supple-
mentary Figure iii, http://links.lww.com/HJH/A299). Elev-
ated levels of fibrillar collagen in perivascular and
interstitial regions (Fig. 3c) in control hearts were signifi-
cantly attenuated by combination treatment (P< 0.01)
(Fig. 3d).
Exposure of H9c2 cardiomyocytes to AngII increased
cell size from 159.2 3.3 to 200.1 3.6mm (P< 0.001)
(Fig. 4a), and this was prevented by MitoQ10 but not
by the control compound dTPP (Fig. 4b). MitoQ10
had no effect on cell size in unstimulated H9c2
cells and cell viability was not affected by MitoQ10 or
dTPP (Supplementary Figure iv, http://links.lww.com/
HJH/A299). Immunofluorescence to detect the MitoQ10
analogue IBTP in cardiomyocytes demonstrated uptake
and colocalization to mitochondria during hypertrophy
(Fig. 4c).orized reproduction of this article is prohibited.
losartan on renal parameters
MitoQ10 Losartan Mþ L
28.10.90 27.61.04 28.10.91
0.170.02 0.220.02 0.200.01
75.810.5 110.58.0 83.67.7
0.840.35 0.850.08 1.070.20
2.000.31 2.140.20 2.180.19
4.921.36 5.741.26 6.020.41
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FIGURE 3 Effect of MitoQ10 alone and in combination with low-dose losartan on cardiac and left ventricular hypertrophy and fibrosis. (a) CMI and (b) LVMI were
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McLachlan et al.DISCUSSION
This study demonstrates that administration of MitoQ10
provides complementary therapeutic benefit to an estab-
lished antihypertensive agent. Our data suggest that
MitoQ10 targets elements of the hypertensive and hyper-
trophic processes involving mitochondrial oxidativeCopyright © Lippincott Williams & Wilkins. Unaut
560 www.jhypertension.comdamage that are not fully addressed by current antihyper-
tensive drugs. Furthermore, our in-vitro studies demon-
strate that MitoQ10 has a direct antihypertrophic action in
cardiomyocytes indicating that its in-vivo action may be
partly independent of blood pressure lowering.
We have previously demonstrated that the mito-
chondria-specific antioxidant MitoQ10 has importanthorized reproduction of this article is prohibited.
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Combined benefit of MitoQ10 and losartan on cardiovascular functionantihypertensive action in young SHRSP [3] emphasizing a
key role for mitochondrial-oxidative stress in the develop-
ment of hypertension. Other in-vivo studies [17–21] have
shown that MitoQ10 is effective against mitochondrial oxi-
dative damage in rodent models of sepsis, cardiac reperfu-
sion, metabolic syndrome and diabetic nephrophathy.
Together, these findings highlight the importance ofCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensiontargeted antioxidant therapy in a range of diseases affected
by mitochondrial oxidative damage.
Several sources of ROS may contribute to the develop-
ment of cardiovascular disease, including NADPH oxidase,
xanthine oxidase, uncoupled nitric oxide synthase (NOS)
and the mitochondrial electron transport chain [1,22–24].
There is a complex interplay between these different ROSorized reproduction of this article is prohibited.
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McLachlan et al.and the precise contributions to the underlying disease
mechanisms remain obscure. There is evidence for
ROS-induced ROS production, with mitochondria being
both stimulated by NADPH oxidases and also acting as
the initiating stimulus for further ROS generation [2,5,24–
26], creating a potential feed-forward cycle of ROS pro-
duction. In the present study, MitoQ10 was tested in
combination with a low-dose commonly prescribed ARB.
This combined therapy demonstrated significant additive
haemodynamic benefit, antihypertrophic and antifibrotic
action when compared with control or single therapies.
Only DBP failed to show additive reduction during com-
bined versus single therapy, suggesting that MitoQ10 and
losartan share a common antihypertensive mechanism for
diastolic pressure. The lack of an additive effect on DBP is
potentially beneficial, as evidence suggests that therapeuti-
cally induced diastolic hypotension can be a risk factor for
increased coronary events [27–29]. In line with the non-
additive effects on DBP, we also observe similar significant
equivalent improvements in aortic nitric oxide bioavailabil-
ity in the combination and losartan-only group. The sig-
nificant reduction in heart rate by MitoQ10 treatment, either
alone or in combination with losartan, during the active
(night-time) period, was not observed with single losartan
therapy. MitoQ10 may alter heart rate by reducing oxidative
stress within the rostral ventolateral medulla (RVLM), as
mitochondrial-derived ROS has been shown to mediate
sympathoexcitation within this brain stem cardiovascular
control centre [30]. We also demonstrate reduced urinary
protein levels in MitoQ10 and combination-treated rats
indicating that mitochondria-specific antioxidants may also
play a role in reducing end-organ damage in the kidney.
Increased ROS production stimulates myocardial fibrosis
and is associated with reduced cardiac function [31]. This
may be due to the accumulation of perivascular collagen
compressing coronary arterioles and the accumulation of
fibrillar collagen in the myocardial interstitium increasing
wall stiffness and impairing cardiac systolic function [32].
Significant cardiac fibrosis has previously been reported in
male SHRSP by 16 weeks of age [33,34], and in the current
study, we demonstrate prevention of cardiac fibrosis by
combination treatment. The design of the current study
does not allow direct mechanistic assessment of the anti-
fibrotic action of MitoQ10. This would require investigation
in alternative models of cardiac fibrosis such as the trans-
verse aortic constriction (TAC) model or the renal hyper-
tensive rat (RHR), permitting pre and postsurgery
assessment of MitoQ10 action. However, we suggest that
the significant reduction in collagen deposition by combi-
nation therapy is likely to be due to decreased oxidative
damage. Losartan lowers blood pressure and decreases
left ventricular hypertrophy by blocking AT1 receptors,
and reducing AngII-dependent activation of NADPH
oxidases, [35,36]. This, in turn, can reduce mitochon-
drial-derived ROS production [24,26] in addition to the
direct mitochondrial antioxidant potential of MitoQ10.
Our data suggest that combining a mitochondria-targeted
antioxidant with losartan may provide superior anti-
hypertensive, antihypertrophic and antifibrotic action
by interrupting the vicious cycle of ROS production
and oxidative damage.Copyright © Lippincott Williams & Wilkins. Unaut
562 www.jhypertension.comAlthough this study was unable to demonstrate direct
MitoQ10-induced improvement in ROS, this was not entirely
unexpected considering that O2
, the primary ROS pro-
duced by the mitochondria, is not readily diffusible across
mitochondrial membranes and is largely dismutated to
H2O2 [37]. Moreover, it is well recognized that measurement
of reactive molecules in biological environments is inher-
ently challenging due to their short lifespan and the limited
selectivity of detection systems [38–40].
Cardiac hypertrophy is an adaptive response to
increased blood pressure, and as a result, practically all
antihypertensive agents reduce LVMI, emphasizing the
importance of haemodynamic load in the pathogenic proc-
ess. However, convincing evidence from studies with low-
dose ACE inhibitors and ARBs also demonstrate blood
pressure independent attenuation of left ventricular hyper-
trophy [7–9]. The beneficial action of MitoQ10 on cardiac
hypertrophy despite modest blood pressure reduction
suggests a direct role for mitochondrial oxidative stress
in the hypertrophic process rather than simply a secondary
effect of blood pressure reduction [3]. In support of this,
H9c2 cardiomyocytes, a well established model of hyper-
trophy [14,15,41], showed dose-dependent inhibition of
hypertrophy by MitoQ10. These data suggest a potentially
important therapeutic role for MitoQ10 in heart disease
independent of its haemodynamic effects.
The current preclinical study has investigated the
beneficial action of MitoQ10 during the developmental of
hypertension and left ventricular hypertrophy. The next
stage will be to determine the effects of mitochondria-
specific antioxidant efficacy in the more clinically relevant
setting of established hypertension. These future studies
will provide important information for potential clinical
trials of human resistant hypertension, as MitoQ10 was
proven well tolerated in two phase II clinical trials [42,43].Clinical perspectives
Oxidative stress and mitochondrial dysfunction are increas-
ingly implicated in cardiovascular disease and yet this is a
neglected aspect in current treatment strategies. We demon-
strate that MitoQ10 is a potential complementary therapeutic
intervention to current antihypertensive agents, particularly
in the treatment of haemodynamic changes and end-organ
damage associated with resistant hypertension.
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Referee 1
The manuscript explores the efficacy of MitoQ10 as a
combination therapy with an angiotensin receptor blocker
in reducing cardiac fibrosis with hypertension. Although,
there are several antihypertensives that can be used clin-
ically to prolong survival in hypertension induced heart
failure, there is still a need to find better therapeutic
molecules. One of the possible targets is reducing the
reactive oxygen species generated by mitochondria thus
limiting cardiac fibrosis and the consequent heart failure.
Among several antioxidants tested so far, none has been
shown to be effective. Something like MitoQ10 may provide
a benefit as combination therapy, provided the animal
experiments are confirmed in humans.Referee 2
There is convincing evidence that oxidative stress is
involved in the pathogenesis of hypertension but data from
clinical trials with antioxidants are inconsistent. Targeting
the enzymes responsible for reactive oxygen species (ROS)
generation could be an effective strategy. Mitochondria is
an important source of ROS at cardiovascular level. This
study shows that the combination of the mitochondria-
targeted antioxidant MitoQ10 and losartan provides additive
effects, attenuating hypertension and left ventricular hyper-
trophy of stroke-prone spontaneously hypertensive rats.
Thus, mitochondria-targeted antioxidants would provide
complementary therapeutic benefit to the inhibitors of
renin-angiotensin-system in the treatment of hypertension.
However, the clinically relevance of the observed effects in
this work are unknown.horized reproduction of this article is prohibited.
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